MetaVia Inc. has begun dosing the first patient in Part 3 of its Phase 1 trial for DA-1726, a novel dual GLP-1/glucagon receptor agonist aimed at treating obesity. This phase tests one-step and two-step dose titrations to safely reach higher doses (48 mg and 64 mg) over 16 weeks, aiming to improve weight loss and tolerability compared to current therapies. Early results showed about 9% weight loss at 48 mg with positive effects on waist size and blood sugar control. Data from this trial are expected by Q4 2026, which could support DA-1726 as a more effective and easier-to-dose obesity treatment.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
